Prosecution Insights
Last updated: November 13, 2026
Application No. 17/786,128

NONIONIC POLYMERIC FATTY ACID COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID-BASED SUBSTRATES, ESPECIALLY HAIR

Non-Final OA §103§112§DOUBLEPATENT
Filed
Jun 16, 2022
Priority
Dec 17, 2019 — provisional 62/948,982 +1 more
Examiner
STEVENS, MARK V
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Momentive Performance Materials GmbH
OA Round
3 (Non-Final)
65%
Grant Probability
Favorable
3-4
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
575 granted / 879 resolved
+5.4% vs TC avg
Strong +42% interview lift
Without
With
+41.6%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
50 currently pending
Career history
950
Total Applications
across all art units

Office Action

§103 §112 §DOUBLEPATENT
DETAILED ACTION Formal Matters Claims 1-106 are cancelled. Claims 148 and 149 are new. Claims 115,117-118,120-123,125-126,138-142,144-145 and 147 are withdrawn. Claims 107-114,116,119,124,127-137,143, 146, 148-149 are under examination. Priority The instant application is a continuation of PCT/IB2020/001058 filed on 12/15/2020, which claims priority from US provisional application 62/948,982 filed on 12/17/2019. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 06/24/2026 has been entered. Objections and Rejections Withdrawn The rejection under USC 103 over Benson US20180125767A1, Blin EP1457193A1 and Baydar US 4857310 is withdrawn per applicant’s arguments and amendments. As these rejections are withdrawn, applicant’s arguments toward these rejections are now moot. Claim Rejections - 35 USC § 112(d) The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 108-111, 128-132 and 148-149 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claims 107 and 127, on which claims 108 and 128, respectively, depend on, now have their formula I or Ia compound limited to III or IIIa respectively, which have r+s=3 and r=1 or 2. Claims 108 and 128 allow r+s to be 2 to 55 and r= 0 to 54, which broadens these options. Thus, claims 108 and 128 are not further limiting of claims 107 and 127, respectively. As claims 109-111, 129-132 and 148-149 are dependent on claims 108 and 128, they also carry these limitations that are not further limiting. Additionally, note that claims 107 and 127 after amendment provide that “R4 contains one or more internal ester groups derived from a dicarboxylic acid and one or two hydroxy carboxylic acids by cross-condensation” while claims 108 and 128 provide for a definition of R4 without this limitation and claims 148-149 provide this same limitation, which is exactly as indicated in claims 107 and 127, which claims 148 and 149 indirectly depend on. Thus, it appears that there is no further limitation presented to the R4 definition by each of these claims when considering what is presented in claims 107 and 127. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 103 The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under pre-AIA 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 107-114,116,119,124,127-137,143, 146 and 148-149 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Blin EP1457193A1, Lawate US5427704A and Isbell (Grasa y aceites, 2011, volume 62, pages 8-20). Although applicant amends the claims, they are in broad form to the number of structures that can be covered. Blin teaches “a cosmetic care or make-up composition containing a) at least one polyester resulting from the esterification of at least one triglyceride of carboxylic acid (s) hydroxylated (s) with a monocarboxylic acid aliphatic and with an aliphatic dicarboxylic acid, and b) at least one pasty compound. This composition makes it possible to obtain a deposit on the slippery, shiny, comfortable, clean contoured keratin materials, which does not migrate, whose color intensity is improved and / or whose color resistance after proofs is improved” (abstract). Blin teaches PNG media_image1.png 287 727 media_image1.png Greyscale pages 14-15 and paragraphs 27-29). R is a chain of 5 to 33 carbon atoms. Blin teaches ricinoleic acid as the preferred triglyceride that is found in natural castor oil (English translation of claims and disclosure). Blin teaches triglyceride being esterified with aliphatic monocarboxylic acid molecules (English translation, hydroxy hydroxylated aliphatic acid (triglyceride) polyester section). Benson teaches “Preferably, the hydroxylated carboxylic acid (s) are chosen from: 12-hydroxy stearic acid; α-hydroxy octadecanoic acid; 14-eicosenoic hydroxy acid, leucinic acid or 2-ethyl 3-hydroxy caprylic acid; ricinoleic acid; 3-hydroxy 4-hexanoic acid or oxynervonic acid; 16-hydroxy 6-hexadecenoic acid; 9,10-dihydroxy octadecanoic acid, 9,12-dihydroxy octadecanoic acid, aleuritic acid, 9,10,12-trihydroxy octadecanoic acid, hexahydroxy octadecanoic acid or octahydroxy octadecanoic acid (English translation). Thus, the fatty acid groups do not all have to be ricinoleic acid in an estolide ester compound. Blin teaches aliphatic dicarboxylic acids like succinic acid for the compounds. Blin teaches providing condensates of dicarboxylic acid and diols/polyols (English translation of Blin, claims of Blin). Blin provides for hair care and cosmetic products (claims of Blin). Blin does not particularly indicate the elected compound of applicant, but provides compound structures that would be estolides based on how the triglycerides are reacted from hydroxyl groups off the fatty chain. Lawate teaches triglyceride oils thickened with estolides of hydroxy-containing triglycerides (abstract and field of invention). Lawate provides general structures in column 2 and those with hydroxyl groups in the fatty chains in column 5 (also see claim 1 of Lawate). Column 3 notes that the estolide would continue to crosslink at the unreacted -OH and -COOH sites to form a polyestolide (column 3, lines 15-51). Lawate indicates that triglyceride oils are environmentally friendly (biodegradable) base fluids in industrial applications and increasing their viscosity making them thicker helps take more advantage of their biodegradability for industrial use (column 1, lines 16-25). Lawate teaches “The carboxylic acid RZCOOH reacted with the hydroxy-containing triglyceride desirably contains from 2 to 24 carbon atoms (acetic acid to tetracosanoic acid) including isomers and unsaturation. Preferred carboxylic acids are the acids of butyric, caproic, caprylic, capric, lauric, myristic, palmitic, stearic, oleic, linoleic, and li- nolenic.” (column 5). Example A-6 allows for “In an even further embodiment, acids other than aliphatic monocarboxylic acids may be reacted with the hydroxy containing triglyceride to form an estolide. These may be aliphatic dicarboxylic acids or aryl mono-, di- or tri- carboxylic acids”. Isbell teaches “Estolides are a developing class of natural and synthetic compounds that have been synthesized from hydroxy oils like castor and lesquerella or by the condensation of fatty acids across the olefin of a second fatty acid” (Summary). Figure 6 of Isbell shows how an estolide linkage is formed between a hydroxyl of a fatty chain (oleic acid) and a carboxylic acid (also see section 3.1 for estolides from hydroxy fatty acids). Table 3 of Isbell provides for castor triglyceride estolides and synthetic glyceride estolides (section 2.2). Isbell indicates that estolides are used in cosmetics and industrial applications (introduction and summary). One of ordinary skill in the art before the time of filing was able to make estolide esters of different carboxylic acid compounds such as fatty acids (e.g. ricinoleic acid and others) and link them together by esterification or to other compounds to make useful compounds for cosmetic products through the combined teachings of the combined prior art that teach esterized estolide compounds with glycerol/polyol and various fatty acids including hydroxy fatty acids. The estolide esters are provided to be advantageous for performance and being eco-friendly and biodegradable products in teachings of Lawate and Isbell provides for producing estolides from triglycerides and carboxylic acids. Therefore, there was a reasonable expectation of success in obtaining ester compounds by combining known triglycerides, fatty acids, carboxylic acids and alcohols along with an esterification process and oligomerization into structures like those of Blin similar of those of applicant’s claims and using them for cosmetic and hair care purposes by the teachings of the prior art due to uses for cosmetic performance/benefit and being environmentally friendly while using teachings of Lawate and Isbell to provide such estolide compounds with triglycerides. Applicant should also consider MPEP 2144.09 where close structural and functional similarity is considered for obviousness of compounds. In this case, the prior art notes cosmetic utility including hair as well as estolides of fatty acid triglyceride compounds. The prior art teaches the groups/components, structures and processes relevant to making such estolide compounds. Non-Statutory Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 107-114,116,119,124,127-137,143, 146, 148 and 149 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 42-46, 49-54, 56-66 of copending Application No. 17/786,081 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of ‘081 provide for structures that have similar formula, components and compositions. PNG media_image2.png 246 591 media_image2.png Greyscale in claims of ‘081. PNG media_image3.png 115 450 media_image3.png Greyscale in applicant’s current claims. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim 107-114,116,119,124,127-137,143, 146 and 148-149 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 60, 62-63, 65-67, 69-71, 74-89, 90, 97-99, 105, 107-110 of copending Application No. 17/840,922 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of ‘922 provide for structures that have similar formula, components and compositions. PNG media_image4.png 88 527 media_image4.png Greyscale in claims of ‘922. in applicant’s current claims. PNG media_image5.png 144 563 media_image5.png Greyscale This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Response to Applicant’s Arguments Applicant argues that it is premature to file terminal disclaimers at this time and does not argue these rejections at this time. Therefore, the rejections over non-statutory double patenting are maintained. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARK V STEVENS whose telephone number is (571)270-7080. The examiner can normally be reached on M-F 9:00 am to 6:00 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian-Yong Kwon can be reached on (571)272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARK V STEVENS/ Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Show 1 earlier event
Jun 16, 2022
Response after Non-Final Action
Sep 08, 2025
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT
Dec 04, 2025
Response Filed
Feb 25, 2026
Final Rejection mailed — §103, §112, §DOUBLEPATENT
May 06, 2026
Response after Non-Final Action
Jun 24, 2026
Request for Continued Examination
Jun 25, 2026
Response after Non-Final Action
Oct 20, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778890
DEVELOPMENT OF A NEW FAMILY OF NANOCARRIERS DERIVED FROM NATURAL TETRAMERIC ACID LIPIDS
2y 5m to grant Granted Nov 03, 2026
Patent 12765573
SOFT CANDY WITHOUT FISHY TASTE OR ODOR AND PREPARATION METHOD THEREOF
2y 11m to grant Granted Oct 20, 2026
Patent 12751917
HYDROGELS AS ORAL DELIVERY DOSAGE FORMS, METHODS OF MAKING AND USING SAME
6y 1m to grant Granted Oct 06, 2026
Patent 12751959
CANNABIDIOL NANODRUG FORMULATIONS AND METHODS FOR USE OF THE SAME
3y 4m to grant Granted Oct 06, 2026
Patent 12751928
PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF SULTIAME
2y 11m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+41.6%)
High
PTA Risk
Based on 879 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month